Review Article

Autologous Mesenchymal Stem Cell Transplantation in Multiple Sclerosis: A Meta-Analysis

Table 1

Basic demographics and clinical characteristics of each included study.

AuthorsSample size, Follow-up, monthAge, yearEDSSMS subtype, %MS duration, yearCell sourceTransplantation way

Bonab et al.1019 (13-26)33 (22-40)5.15 (3.5-6)SPMS (80%) PPMS (20%)11.2 (3-21)Bone marrowIntrathecal injection

Karussis et al.1566.7 (4-8)NA10.7 (5-15)Bone marrowIntrathecal and intravenous injection

Yamout et al.71242 (34-49)6.5 (4.5-7.5)SPMS (100%)19.9 (11-39)Bone marrowIntrathecal injection

Bonab et al.221235.2 (23-50)6.2 (5.5-7)SPMS (91%) PRMS (9%)8.68 (5-14)Bone marrowIntrathecal injection

Connick et al.101248.8 (40–53)6.1 (5.5–6.5)SPMS (100%)14.4 (5–26)Bone marrowIntravenous injection

Harris et al.688.8 (48-96)43 (28-64)7.3 (6.5-9)SPMS (67%) PPMS (33%)17 (7-27)Bone marrowIntrathecal injection

Cohen et al.6126 (3–6.5)SPMS (58%) RRMS (42%)Bone marrowIntravenous injection

Fernández et al.1912SPMS (100%)AdiposeIntravenous injection

Harris et al.201249 (27-65)6.8 (3.5-8.5)SPMS (80%) PPMS (20%)18.8 (10-32)Bone marrowIntrathecal injection